Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MUnLbY5ie2ViQYPzZZk> MlnrNlQhcA>? NFX1XYNKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= MkPuNlQ3PDFzMEO=
COLO205 NWPpOGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HQWVczKGh? MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=> NUHvVlN4OjR4NEGxNFM>
U937 NGfKN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64O|IhcA>? NGXsc5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO NUHsTVlwOjR4NEGxNFM>
MOLM13 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NkBp MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN M4X2cFI1PjRzMUCz
MOLM13 M37Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp NUXGOG9SSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB{d3KjZnXubYIuemW|aYP0ZY51KGi3bXHuJG1QVE1zMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW62bzDEUmEhf2m2aDDJR|UxKG:oIECuNFk3KM7:TR?= NXTnR3lCOjR4NEGxNFM>
MDA-MB-435 M2m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOyOEBp NGLvflVKSzVyPUCuNVYh|ryP MmjuNVU5ODF6M{G=
K562 MXnDfZRwfG:6aXOgRZN{[Xl? NUe3eFd2QTZiaB?= Mn[xSG1UVw>? MmSwTWM2OD1{IN88US=> NWXQTXNoOjR2MUe1OlY>
DU145 NI\QXGVEgXSxdH;4bYMhSXO|YYm= M2jk[Fk3KGh? NUPJO4tDTE2VTx?= M1LBXWlEPTB;Nz61JO69VQ>? NEDmRZMzPDRzN{W2Oi=>
MDA-MB-231 NUfjTJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTUdVNNOSEQvF2= MYqyOEBp NUS5UFRLTE2VTx?= NGW5fHpE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MlizNlQ1OTd3Nk[=
MCF7 NHTp[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3rNUDPxE1? NXXlXYt5OjRiaB?= NH:3epdFVVOR NF62O3dE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MYmyOFQyPzV4Nh?=
MCF7 MlnQT4lv[XOnIFHzd4F6 MXy1JO69VQ>? NXXFe4E{OjRiaB?= NUT6NIF4TE2VTx?= NUjwSnJzUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> M2fqRlI1PDF5NU[2
MDA-MB-231 MnXJT4lv[XOnIFHzd4F6 NYnQelZSPSEQvF2= NWi3flJsOjRiaB?= NYLJW2czTE2VTx?= NF3RNXpKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw M{O3TVI1PDF5NU[2
MDA-MB-231 MUfGeY5kfGmxbjDBd5NigQ>? MkDzNU0yOCEQvF2= M2ixblI1KGh? NU\0e|Z[TE2VTx?= NVrRU3Iy\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MmXJNlQ1OTd3Nk[=
MCF7 MlSzSpVv[3Srb36gRZN{[Xl? NVLxTIZwOS1zMDFOwG0> MmXCNlQhcA>? Ml3DSG1UVw>? M3\sOYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= MofpNlQ1OTd3Nk[=
MDA-MB-231 M{DSNWZ2dmO2aX;uJGF{e2G7 Mn\LNE42NTFizszN M2rifVQ5KGh? MnLmSG1UVw>? M1zLOohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm NGPF[XIzPDRzN{W2Oi=>
MCF7 MXLGeY5kfGmxbjDBd5NigQ>? NYW2c|lOOC53LUGg{txO NHzDVGQ1QCCq NIfBXJhFVVOR NYDiNmVQcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NUPFdW03OjR2MUe1OlY>
697 M1j3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW3PWtsUUN3ME2xOFgvOzhibl2= NYroNJE1W0GQR1XS
P12-ICHIKAWA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz0TWM2OD17Nj6wOEBvVQ>? MYPTRW5ITVJ?
NB69 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PIfWlEPTB;MU[xMlghdk1? MYjTRW5ITVJ?
EoL-1 M4DEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZUGlEPTB;MUi3MlI3KG6P NYXtfIo4W0GQR1XS
BHT-101 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTmTWM2OD1zOUiuNlUhdk1? NEnGXGpUSU6JRWK=
SK-NEP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LMb2lEPTB;MkKwMlAzKG6P M1m2XnNCVkeHUh?=
MHH-NB-11 NVXNWZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDmNnBXUUN3ME2yNlAvOTlibl2= MXPTRW5ITVJ?
AsPC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHzRW1KSzVyPUK1Nk42OyCwTR?= NFHM[otUSU6JRWK=
ES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW2TWM2OD1{NU[uNlUhdk1? NX\MdoM5W0GQR1XS
LAMA-84 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXsTWM2OD1{NUiuNVkhdk1? NGPRc45USU6JRWK=
MOLT-16 M4r5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv6fWZKSzVyPUK1PE41QSCwTR?= M1TYWXNCVkeHUh?=
ES7 NG\Oc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDpUYVZUUN3ME2yO|MvODlibl2= M1PidHNCVkeHUh?=
KY821 NGniSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPXTWM2OD1|MUSuNUBvVQ>? M17MZnNCVkeHUh?=
RT-112 NUHj[o1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG2W5NKSzVyPUOyNU4xPSCwTR?= NInUVVBUSU6JRWK=
HL-60 NX;HXGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jMVmlEPTB;M{SwMlY3KG6P MXnTRW5ITVJ?
MOLT-4 NFvZVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r0c2lEPTB;M{S1MlE{KG6P MWfTRW5ITVJ?
KARPAS-45 M4PB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf0dXhKSzVyPUO3Ok4yPiCwTR?= M{\hTHNCVkeHUh?=
SK-N-AS NHXnTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi0ZmRKSzVyPUO4O{45OyCwTR?= NIjDXnBUSU6JRWK=
CTB-1 M3z2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[yNmlEPTB;NEC1MlAzKG6P MoPYV2FPT0WU
NKM-1 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjLTXhKSzVyPUSxNU45QSCwTR?= MUfTRW5ITVJ?
HTC-C3 NF\NclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLpV3hFUUN3ME20N|IvQTVibl2= NVn0fZJKW0GQR1XS
BE-13 NF7LOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjh[oduUUN3ME20OFQvOjdibl2= NWT4NmpvW0GQR1XS
KOSC-2 NXzwSHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHhTWM2OD12Nk[uPUBvVQ>? MWnTRW5ITVJ?
NB14 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR6Mz61PEBvVQ>? NWDQbWFGW0GQR1XS
CAL-27 NUDoUGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH6[nBvUUN3ME20PVQvPTlibl2= M3K2bnNCVkeHUh?=
H9 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm4SGlPUUN3ME20PVUvPDNibl2= MlTzV2FPT0WU
RS4-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVyND63N{BvVQ>? NInE[GlUSU6JRWK=
PA-1 NX;HWpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[3Wpp2UUN3ME21NFkvQDZibl2= MVLTRW5ITVJ?
MV-4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW2dWpKSzVyPUWxN{45PSCwTR?= M{HxSnNCVkeHUh?=
OS-RC-2 NX7seYJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTV{MT62NkBvVQ>? MY\TRW5ITVJ?
RPMI-8226 NHnvblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nKdmlEPTB;NUK2Mlg3KG6P Ml;JV2FPT0WU
HGC-27 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHrdJRKSzVyPUW2OE46QSCwTR?= MljlV2FPT0WU
CHP-212 M{i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHrc25KSzVyPUW5N{42QSCwTR?= NFTRVHVUSU6JRWK=
NB10 NGLBbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;YTWM2OD13OUmuNVghdk1? MULTRW5ITVJ?
HH NEnPcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjoTWM2OD13OUmuOFMhdk1? NGjvcZVUSU6JRWK=
EW-16 Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDrZ2hKSzVyPU[wN{42OiCwTR?= M3PjUnNCVkeHUh?=
ES8 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZyNT6yNUBvVQ>? NIjJVZhUSU6JRWK=
HAL-01 M3yxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2eZZKUUN3ME22NFUvPjdibl2= NXe3VW1MW0GQR1XS
A204 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi0XpVKSzVyPU[zN{46OSCwTR?= NGXQ[mNUSU6JRWK=
MHH-PREB-1 M4XCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnLUWF{UUN3ME22N|YvQTlibl2= NVnjOJZwW0GQR1XS
EM-2 NUjBNohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW1TWM2OD14NUCuOlQhdk1? MojBV2FPT0WU
BV-173 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;iWlhKSzVyPU[1Nk41QCCwTR?= Mnv1V2FPT0WU
ONS-76 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\qc3ROUUN3ME22O|cvQDJibl2= MXvTRW5ITVJ?
KM-H2 M2C2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi3TWM2OD14OUWuOVQhdk1? MlzsV2FPT0WU
D-263MG NGnrOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdzNz6xNkBvVQ>? M3HZU3NCVkeHUh?=
ES3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD15MkiuPVMhdk1? MlHMV2FPT0WU
VA-ES-BJ NYTyeVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TKXmlEPTB;N{OyMlI4KG6P Mn7HV2FPT0WU
NBsusSR NWn3RolET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTd2Mj65PUBvVQ>? M2HOSXNCVkeHUh?=
NCI-H520 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojLTWM2OD15NE[uOVIhdk1? NG\4SpNUSU6JRWK=
ES5 NYW5Z5ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Q[nNKSzVyPUe1Nk45KG6P NVrq[oJMW0GQR1XS
T-24 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\SUno1UUN3ME23O|gvPzFibl2= M3LDN3NCVkeHUh?=
SW962 NFT0SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjxc4xKSzVyPUiwPE43OyCwTR?= MkHRV2FPT0WU
EW-3 NV\hWGZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRThyOD63OkBvVQ>? NIKzUGdUSU6JRWK=
RXF393 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRThzMj63PUBvVQ>? MVPTRW5ITVJ?
U251 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRThzMz64PEBvVQ>? M3XYWXNCVkeHUh?=
CAMA-1 M3Hmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT3TWM2OD16M{OuPVQhdk1? MkHtV2FPT0WU
JVM-3 NV;3b2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHFT|RKSzVyPUi1NU44QCCwTR?= NUKyTlBHW0GQR1XS
COLO-800 M2T6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTh7Nz63PEBvVQ>? NVmzNJF7W0GQR1XS
OVCAR-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSyb4RKSzVyPUmwNE4yKG6P M4HVN3NCVkeHUh?=
LB1047-RCC NV\pcmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXydZNYUUN3ME25NlcvPTZibl2= NV:xOI5mW0GQR1XS
SW954 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnYSoNyUUN3ME25NlkvPDFibl2= MXzTRW5ITVJ?
J-RT3-T3-5 NV;6[Fc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1TWM2OD17M{[uNFYhdk1? NWX1bZhWW0GQR1XS
Mewo M4L0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnJNYdKSzVyPUmzOk43KG6P M1HrT3NCVkeHUh?=
NCI-H1770 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITEeFBKSzVyPUm0NE42PSCwTR?= NGX1eZVUSU6JRWK=
HO-1-N-1 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m2[mlEPTB;OU[yMlgyKG6P NGfueG5USU6JRWK=
HSC-3 M4njfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS2TWM2OD17Nk[uOFghdk1? MWXTRW5ITVJ?
TYK-nu NGK5eWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\GU5lSUUN3ME25PVgvOjVibl2= M17vXHNCVkeHUh?=
KYSE-150 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvpTWM2OD1zLkCwNFc3KM7:TR?= MX7TRW5ITVJ?
SN12C MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPETWM2OD1zLkCwPFc2KM7:TR?= NUfTb2VWW0GQR1XS
MOLT-13 NV33THo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X4RmlEPTB;MT6wNVQzOSEQvF2= MVLTRW5ITVJ?
TE-11 NGTV[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\YTWM2OD1zLkC0PFEzKM7:TR?= NILsXoVUSU6JRWK=
DB NG\vTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwMEeyO|Mh|ryP NVPuW5Y6W0GQR1XS
CAL-39 NH3KZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwMEe1NlIh|ryP NX;i[VVXW0GQR1XS
A3-KAW M170Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHruOYRKSzVyPUGuNFg1ODhizszN M1PMb3NCVkeHUh?=
CHP-134 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XGTmlEPTB;MT6xNVgxPyEQvF2= MXjTRW5ITVJ?
TGW Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMUKzPVUh|ryP MlOyV2FPT0WU
QIMR-WIL M1PUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G1OWlEPTB;MT6xN|E{PCEQvF2= MX;TRW5ITVJ?
NCI-SNU-1 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwMU[zOVQh|ryP M2HQdnNCVkeHUh?=
CGTH-W-1 NE\1UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0RnhkUUN3ME2xMlE4OTh4IN88US=> MVvTRW5ITVJ?
MHH-ES-1 NV;Pem9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD1zLkG3PVg3KM7:TR?= MYXTRW5ITVJ?
LB2241-RCC M{\LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i5PWlEPTB;MT6xPFYzKM7:TR?= M4TldHNCVkeHUh?=
ML-2 NH3KeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64dHBtUUN3ME2xMlIxPzN2IN88US=> NEXUWJNUSU6JRWK=
COR-L23 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonXTWM2OD1zLkKyPVM{KM7:TR?= M{D1NXNCVkeHUh?=
BFTC-905 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMkSyOlch|ryP NFyye4FUSU6JRWK=
Hs-578-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPsPYVKSzVyPUGuNlU5OTdizszN M{DSN3NCVkeHUh?=
KG-1 M4TnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PVZWlEPTB;MT6yOlY5PiEQvF2= MYfTRW5ITVJ?
HEL NWfHTVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr5e4cyUUN3ME2xMlI6OzN6IN88US=> MnHZV2FPT0WU
A549 M4Dqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hZoxKUUN3ME2xMlI6Ozl7IN88US=> NFLKd5RUSU6JRWK=
COLO-741 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD1zLkOyNFg6KM7:TR?= MWLTRW5ITVJ?
PC-3 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\hVGlEPTB;MT6zOVIzOSEQvF2= MYTTRW5ITVJ?
HOS M3i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwM{WyPVYh|ryP NY\vdZd2W0GQR1XS
HT-1080 NUnOZWk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwM{e1NVkh|ryP M{P2eXNCVkeHUh?=
TE-8 NUfZR|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvCTGJLUUN3ME2xMlQyPzd2IN88US=> M2HGSHNCVkeHUh?=
BHY MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPZdGpHUUN3ME2xMlQ3QTJ|IN88US=> MXPTRW5ITVJ?
BB65-RCC M{nON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[3WZd4UUN3ME2xMlUxPTJ6IN88US=> MlrtV2FPT0WU
HN MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHKTWM2OD1zLkW0NFcyKM7:TR?= NELtTI9USU6JRWK=
NCI-H441 NYTQTVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwNUS5NFch|ryP MXnTRW5ITVJ?
RPMI-8866 M2P4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwNUi1NFch|ryP M3G3VXNCVkeHUh?=
CAL-62 NEW4[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3L[2NKSzVyPUGuOlA5PjJizszN M2\ZN3NCVkeHUh?=
MG-63 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnJSmdrUUN3ME2xMlYyQDF|IN88US=> NHS1THFUSU6JRWK=
SK-LU-1 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WxPGlEPTB;MT62NlE2OiEQvF2= MUXTRW5ITVJ?
BCPAP MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwNk[0OVch|ryP MYXTRW5ITVJ?
22RV1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjrOWpKSzVyPUGuOlc5PDNizszN MVPTRW5ITVJ?
T47D NGraWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HPUmlEPTB;MT62PFA3OSEQvF2= MnjzV2FPT0WU
MSTO-211H NGK4XHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjxTWM2OD1zLk[5OlA{KM7:TR?= M17ofnNCVkeHUh?=
DEL Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S1WGlEPTB;MT63NFI4OyEQvF2= Mor3V2FPT0WU
H4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwN{OyNVIh|ryP NH:4U3dUSU6JRWK=
CAL-51 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3mTWM2OD1zLke0PFU2KM7:TR?= M3K2[nNCVkeHUh?=
ABC-1 NIrNWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwN{i1PFIh|ryP MWXTRW5ITVJ?
MZ2-MEL NFvGNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGxbVY4UUN3ME2xMlc6PTR{IN88US=> M4HhSXNCVkeHUh?=
YKG-1 NH\pWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jHZmlEPTB;MT64NVA3OSEQvF2= MkL4V2FPT0WU
KM12 M{HDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwOEG2NFIh|ryP MoTGV2FPT0WU
L-363 NVTs[VdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTF[JlKSzVyPUGuPFc1OTJizszN MkLPV2FPT0WU
KU812 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwOEmyPFIh|ryP M2L2cHNCVkeHUh?=
LOXIMVI NFjwS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPkTWM2OD1zLkmxNlI5KM7:TR?= MkDuV2FPT0WU
G-401 NVTnUoV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;SWmlEPTB;MT65NlQzQCEQvF2= NIXMfo1USU6JRWK=
SW780 M1;iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwOU[yOFYh|ryP MVPTRW5ITVJ?
SW872 M1LGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXmb4dKSzVyPUGuPVg{OyEQvF2= MlezV2FPT0WU
NB7 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELPdJNKSzVyPUGuPVk{OjNizszN M3;vV3NCVkeHUh?=
T98G M4GxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK4d3JKSzVyPUKuNFA3PjZizszN M1XkR3NCVkeHUh?=
SW1710 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK1TWM2OD1{LkC2PVQ2KM7:TR?= NX35ZWlIW0GQR1XS
NCI-H1573 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XveWlEPTB;Mj6wO|I6QCEQvF2= M2\DU3NCVkeHUh?=
KE-37 NHLObm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwMEi5OVEh|ryP NE\BNZhUSU6JRWK=
786-0 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGyc49KSzVyPUKuNVU1OzlizszN M4HqeHNCVkeHUh?=
SAS M3XSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XGXmlEPTB;Mj6yNFM4PCEQvF2= NILKNXBUSU6JRWK=
CAL-54 NV;mZmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki5TWM2OD1{LkKwOFE{KM7:TR?= MY\TRW5ITVJ?
SF268 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwMkOxNlIh|ryP MUfTRW5ITVJ?
SW620 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDUSpBKSzVyPUKuNlYyPjlizszN Mnr1V2FPT0WU
MN-60 M1HoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vFemlEPTB;Mj6zNVA3KM7:TR?= NFnUOW1USU6JRWK=
EFO-27 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\5NHJIUUN3ME2yMlMzODV6IN88US=> M13YenNCVkeHUh?=
NCI-H747 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwM{KxPVkh|ryP MUnTRW5ITVJ?
HCC2218 M{GzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJwM{WzO|Qh|ryP NU\Kb5QzW0GQR1XS
MIA-PaCa-2 M1;J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XJS2lEPTB;Mj6zOlQ{PyEQvF2= NUjM[JJ4W0GQR1XS
SJSA-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwM{e3PVYh|ryP MUDTRW5ITVJ?
RKO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkToTWM2OD1{LkO4OFk3KM7:TR?= MVXTRW5ITVJ?
NB6 NH22flBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3raWWlEPTB;Mj60NFM4PCEQvF2= MVHTRW5ITVJ?
ES4 M1LyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvxfWxMUUN3ME2yMlQ2PDJ{IN88US=> M1HvSnNCVkeHUh?=
EGI-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWwTmxKSzVyPUKuOFY5QDNizszN NV:xPZZPW0GQR1XS
CTV-1 NYLObJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL1SGtKSzVyPUKuOVI4PzNizszN M4XBTXNCVkeHUh?=
NCI-H1355 M3vv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwNUW5OVEh|ryP NVHGZWdIW0GQR1XS
GT3TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j4eGlEPTB;Mj61PVE6QSEQvF2= NGmwNoFUSU6JRWK=
SK-HEP-1 M1rOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwNUmyOlYh|ryP NILTNIZUSU6JRWK=
GAMG NY\heHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK1TWM2OD1{LkW5N|k1KM7:TR?= M2fWPXNCVkeHUh?=
SK-MES-1 NIXmcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTGTWM2OD1{Lk[xPFA{KM7:TR?= M4\venNCVkeHUh?=
RO82-W-1 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSzflJmUUN3ME2yMlYzODV5IN88US=> MUfTRW5ITVJ?
ECC10 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rCV2lEPTB;Mj63NFIxPiEQvF2= M{\ic3NCVkeHUh?=
MCF7 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGxd|dFUUN3ME2yMlcyPDZ2IN88US=> MV\TRW5ITVJ?
D-283MED NFrlUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfBcHJtUUN3ME2yMlczPDNizszN MXfTRW5ITVJ?
RPMI-7951 M{WxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4OHVyUUN3ME2yMlc2Pjl2IN88US=> NYfLd|lHW0GQR1XS
Ramos-2G6-4C10 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Kw[GlEPTB;Mj63O|A6QSEQvF2= MYfTRW5ITVJ?
KGN NIXoZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlPJlyUUN3ME2yMlgyQDh2IN88US=> MlPqV2FPT0WU
NUGC-3 M1qzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD1{LkiyOVA2KM7:TR?= NX7QOlJUW0GQR1XS
NCI-H292 NGTmPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXZPXBxUUN3ME2yMlg2ODV|IN88US=> Mn3BV2FPT0WU
Becker NVKyVI5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj4bHlKSzVyPUKuPVU5OzJizszN Mn7FV2FPT0WU
NCI-H1299 NIq5eWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHqTWM2OD1|LkC1NlY{KM7:TR?= MlWyV2FPT0WU
ETK-1 NH64ZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL0ZpRYUUN3ME2zMlA2PDNizszN Mk\wV2FPT0WU
TK10 M4jKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfQTWM2OD1|LkKwNVY2KM7:TR?= NWrHTXhxW0GQR1XS
VMRC-RCZ MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC0TWpKSzVyPUOuN|Y1QDhizszN M{izPXNCVkeHUh?=
YH-13 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTlTWdKSzVyPUOuOFQxPzlizszN M{KyenNCVkeHUh?=
DU-145 NV;ZUFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmxfIRKSzVyPUOuOFYzPjlizszN NIXX[m1USU6JRWK=
SW1088 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\mZmlEUUN3ME2zMlQ4PDdizszN MmWwV2FPT0WU
HOP-92 NG\DN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32zd2lEPTB;Mz61NFM1OiEQvF2= MnTYV2FPT0WU
KP-N-YS M1nJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj3VmlKSzVyPUOuOlIyOzlizszN NEDVc2lUSU6JRWK=
NCI-H460 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwNk[3N{DPxE1? MkXOV2FPT0WU
U-2-OS MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vMOmlEPTB;Mz63NlU{PSEQvF2= NFvkZXhUSU6JRWK=
A101D NWHm[lZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYUmlEPTB;Mz63Olk{PiEQvF2= MXfTRW5ITVJ?
MDA-MB-231 NVXHZYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrGT4hZUUN3ME2zMlgyQTVzIN88US=> NILwXm5USU6JRWK=
IST-MES1 NWTxbYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\mWWlEPTB;Mz64N|Ih|ryP NXPxT2xWW0GQR1XS
COR-L105 NWjUUm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTRwMEG4JO69VQ>? MYrTRW5ITVJ?
NCI-H1437 NH7BRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHJW2FNUUN3ME20MlAzOzB{IN88US=> M3zG[HNCVkeHUh?=
CAL-85-1 NXrZdZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7WNYFRUUN3ME20MlAzPDZzIN88US=> M1:4enNCVkeHUh?=
MZ1-PC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRwMUi1OVYh|ryP NUTQd4xTW0GQR1XS
VM-CUB-1 NH3LUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv1TWM2OD12LkOxNlg1KM7:TR?= MkDQV2FPT0WU
CHL-1 M{XNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnrWY1KSzVyPUSuN|IyPjlizszN NFLyeYpUSU6JRWK=
MDA-MB-361 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRwM{OxOVMh|ryP NVSw[|N4W0GQR1XS
NCI-H661 NVT5dZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH1TWM2OD12LkWwNFkzKM7:TR?= MXzTRW5ITVJ?
EW-11 NYPMOmRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXUOpJKSzVyPUSuOVIzOzFizszN MYrTRW5ITVJ?
BEN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrPNYsxUUN3ME20MlUzQDF3IN88US=> NXGwfIR7W0GQR1XS
BFTC-909 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;kTWM2OD12LkW2Nlc2KM7:TR?= M{fXOHNCVkeHUh?=
NCI-H2087 NIX3R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwNUixOlQh|ryP NXXUZ2FFW0GQR1XS
RVH-421 NGe1Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYZWlKSzVyPUSuOlY3QSEQvF2= NEnUcpJUSU6JRWK=
P30-OHK NXjBW5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7KXWNsUUN3ME20MlY5ODB6IN88US=> NEiwOpdUSU6JRWK=
NCI-H28 NWLKdWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwOEG2OlEh|ryP NHnrOVlUSU6JRWK=
ES6 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwOEOwNVYh|ryP Mn63V2FPT0WU
769-P M{nxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTRwOEW5NlYh|ryP MlLmV2FPT0WU
OE33 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwOEixOlEh|ryP NXTN[ZQ5W0GQR1XS
SW982 NXjjTnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uyXmlEPTB;ND65OVA3OSEQvF2= MojwV2FPT0WU
A388 NIjVN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LtZ2lEPTB;NT6wNlk5OyEQvF2= MXnTRW5ITVJ?
TI-73 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwME[xPVQh|ryP M2Tqe3NCVkeHUh?=
HCT-116 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjCSlVKSzVyPUWuNFk5QDlizszN MlHpV2FPT0WU
HuP-T3 NGXkfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPufFFmUUN3ME21MlE5PzB7IN88US=> MUfTRW5ITVJ?
G-402 NF3QUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH1TWM2OD13LkG5OFE3KM7:TR?= Mo\lV2FPT0WU
NCI-H1792 M2DBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXLdFN4UUN3ME21MlI1PjJ{IN88US=> NUDHc2hkW0GQR1XS
NCI-H209 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJNGlEPTB;NT6yOVk1OiEQvF2= NVXzXJoyW0GQR1XS
NCI-H1650 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTVwM{C2N|Qh|ryP M1TObHNCVkeHUh?=
LCLC-97TM1 NXXnRoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0fGlEPTB;NT6zNVgxQCEQvF2= NVztOm5GW0GQR1XS
S-117 NEDkWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDITWM2OD13LkO2PVc3KM7:TR?= MnfwV2FPT0WU
GI-ME-N M33xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mwSWlEPTB;NT6zPVY5OSEQvF2= MVzTRW5ITVJ?
NCI-H2122 NIT1WZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n3OGlEPTB;NT60PVM6PyEQvF2= MWfTRW5ITVJ?
NCI-H1793 NVXRTVltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfETWM2OD13Lk[3OVk{KM7:TR?= MWTTRW5ITVJ?
C2BBe1 NF7LfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fyTGlEPTB;NT63NFA5QCEQvF2= NXr0U5k1W0GQR1XS
TE-12 NIfX[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTVwOEC1OVYh|ryP NG\RdlRUSU6JRWK=
LCLC-103H NX\UR2doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwOUG3JO69VQ>? MXPTRW5ITVJ?
A673 NXPxdGtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrUTWM2OD13LkmxPVMzKM7:TR?= Mk\oV2FPT0WU
BB30-HNC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\qeHJKSzVyPUWuPVg{PiEQvF2= NV7seGxQW0GQR1XS
SF295 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTZwMEC0NlIh|ryP Ml7DV2FPT0WU
KU-19-19 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PWXGlEPTB;Nj6wNVc{OSEQvF2= MofHV2FPT0WU
CFPAC-1 M{HGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juUWlEPTB;Nj6wOFQ1OyEQvF2= MXLTRW5ITVJ?
LoVo NVn3UYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZwMEWwOlMh|ryP MkiyV2FPT0WU
8505C MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j6PGlEPTB;Nj6wO|U4OyEQvF2= Ml\3V2FPT0WU
GMS-10 NITKZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZwMUWwNFIh|ryP MlfWV2FPT0WU
Ca9-22 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDkW|RKSzVyPU[uNVY4OSEQvF2= NXm0OJFMW0GQR1XS
DOK MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TIN2lEPTB;Nj6yNlA4OiEQvF2= MkX2V2FPT0WU
FADU MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTZwMk[wN|kh|ryP M4D2WnNCVkeHUh?=
BxPC-3 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\XcmdtUUN3ME22MlI4OzJizszN MmTuV2FPT0WU
CAL-33 NVzmXmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZwMkmyNFEh|ryP MVvTRW5ITVJ?
SHP-77 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXOS2lOUUN3ME22MlMyPTF{IN88US=> MYDTRW5ITVJ?
LXF-289 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLYNlloUUN3ME22MlM{PDV3IN88US=> M3XOWHNCVkeHUh?=
GB-1 NXXnPJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwM{iyJO69VQ>? NIfJV5BUSU6JRWK=
KS-1 NUPVU3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\DO2t5UUN3ME22MlM5PDR5IN88US=> M2DPXXNCVkeHUh?=
D-502MG NWHBZ3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZwNEKzO|Yh|ryP Mlf3V2FPT0WU
LAN-6 M1S4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;nfmRKSzVyPU[uOVExOjNizszN MnPSV2FPT0WU
H-EMC-SS M2PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\y[5FKSzVyPU[uOVYyPDdizszN M4rScnNCVkeHUh?=
LC-2-ad MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lmd2lEPTB;Nj62NFA4PiEQvF2= M2LoUHNCVkeHUh?=
NCI-H1693 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzjTWM2OD14Lk[yNlE2KM7:TR?= M1vI[HNCVkeHUh?=
SK-N-FI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrFOHlKSzVyPU[uO|UxPDRizszN M4fTOXNCVkeHUh?=
D-423MG NXjUcohyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDXXohSUUN3ME22Mlc3OTF5IN88US=> Mn34V2FPT0WU
KNS-42 NWD2N4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXTN4lKSzVyPU[uO|gyQTdizszN NFTYOnJUSU6JRWK=
GCT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezWYZKSzVyPU[uPVM5KM7:TR?= MVzTRW5ITVJ?
DSH1 NEPKO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjPN4VsUUN3ME23MlA3OzNizszN M4S3UnNCVkeHUh?=
D-247MG MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr3TWM2OD15LkC3PFgyKM7:TR?= MXHTRW5ITVJ?
NCI-SNU-5 M1PwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH3PJRKSzVyPUeuNVg{PzFizszN NImzcZJUSU6JRWK=
TE-6 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTHTWM2OD15LkKwOlAyKM7:TR?= NF\CbmFUSU6JRWK=
NOMO-1 NH;uO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXu[opKSzVyPUeuNlIyOjdizszN M37WXHNCVkeHUh?=
NB17 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTdwM{CzNFkh|ryP NUL5NJVkW0GQR1XS
EW-22 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfnWGM1UUN3ME23MlM1OzR6IN88US=> NGfwWYlUSU6JRWK=
EW-13 NYD5OWNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTmTWM2OD15LkO1NVYzKM7:TR?= MlHsV2FPT0WU
DOHH-2 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjuTWM2OD15LkS0NFIh|ryP MmflV2FPT0WU
TGBC1TKB NUjsNIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof5TWM2OD15LkS5PFk6KM7:TR?= MWjTRW5ITVJ?
GR-ST NV\oUXd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXq[2xLUUN3ME23MlUzPTl2IN88US=> MVjTRW5ITVJ?
KYSE-520 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\oNmxCUUN3ME23MlU2PTF3IN88US=> MU\TRW5ITVJ?
CAPAN-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[4c|V3UUN3ME23MlU6PTFizszN NEnuXWtUSU6JRWK=
HCE-4 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDOZ5MyUUN3ME23MlYzOjd7IN88US=> NV7BR|J5W0GQR1XS
MLMA M2fCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\PO2lEPTB;Nz62Nlk2PyEQvF2= MofSV2FPT0WU
HT-144 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfxbm9mUUN3ME23MlY2OzZ6IN88US=> NGLwfHlUSU6JRWK=
KYSE-180 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD15LkexNVY6KM7:TR?= NUj2Z|VjW0GQR1XS
TE-5 NWH6XnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTdwOUW5O|Eh|ryP M3vt[XNCVkeHUh?=
IGROV-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInJT4hKSzVyPUeuPVg2PTFizszN Moe5V2FPT0WU
NCI-H1581 NHjNTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRThwMEGyJO69VQ>? NIDieZVUSU6JRWK=
SW1990 M{m5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDtTWM2OD16LkC0OlU6KM7:TR?= MXfTRW5ITVJ?
EFM-19 NF3QTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXY[YJKSzVyPUiuNFg2PDVizszN MlPLV2FPT0WU
OGR-1 M1nicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLGXmhKSzVyPUiuOFMxOjNizszN NX7Rc2R6W0GQR1XS
U-118-MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThwNEO0OlMh|ryP M2fOV3NCVkeHUh?=
SK-OV-3 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj0SYdGUUN3ME24MlQ3PzZ3IN88US=> M2r4OXNCVkeHUh?=
KNS-62 NWHaTW84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnQWYNxUUN3ME24MlUyPzZzIN88US=> NVv6fXRNW0GQR1XS
GOTO M2PuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDOflFxUUN3ME24MlU4PjN3IN88US=> NXPBPXQ4W0GQR1XS
8305C MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD5VnR[UUN3ME24MlcxPDh2IN88US=> MWfTRW5ITVJ?
RPMI-2650 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12yW2lEPTB;OD63NVk2PSEQvF2= NX[xdmROW0GQR1XS
NEC8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorUTWM2OD16Lke0N|A4KM7:TR?= NXTiR493W0GQR1XS
KYSE-450 M4\WSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRThwOE[1OFgh|ryP NXXsbGNWW0GQR1XS
RMG-I NXPielA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17PU2lEPTB;OT6xOFA2QCEQvF2= NYPEN5BLW0GQR1XS
CAKI-1 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3yc|d4UUN3ME25MlMyQTd7IN88US=> NUTqenlsW0GQR1XS
KYSE-510 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTlwM{W3O|gh|ryP M{G1SHNCVkeHUh?=
A4-Fuk NGnnSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLVcGN6UUN3ME25MlM3PzBzIN88US=> M2jC[nNCVkeHUh?=
AN3-CA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lu[2lEPTB;OT60OVQ1PCEQvF2= NXnEUG1TW0GQR1XS
SK-N-DZ MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDwRmxPUUN3ME25MlczQDR7IN88US=> MkL2V2FPT0WU
HSC-2 NFm0eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H3[mlEPTB;OT63OlYzQSEQvF2= MmH6V2FPT0WU
EW-1 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWwVlRKSzVyPUmuO|k{PjlizszN MXrTRW5ITVJ?
D-566MG M3XLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwOEO2OlQh|ryP MlXjV2FPT0WU
COLO-792 NYDTWFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPjU3NnUUN3ME25Mlk5PzR4IN88US=> MljKV2FPT0WU
TE-10 NEfGU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXrd3ZoUUN3ME2xNE4xOzl4IN88US=> NXvpcYZjW0GQR1XS
NCI-H650 NHSyNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFyLkSyPFYh|ryP M2HxXXNCVkeHUh?=
U-266 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:5T2lEPTB;MUCuOFU2KM7:TR?= NHP5cFlUSU6JRWK=
Detroit562 M3PFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi1TWM2OD1zMT6wOVE2KM7:TR?= MnLpV2FPT0WU
NH-12 NFPmeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofvTWM2OD1zMT6xOFQ3KM7:TR?= NIHkNHhUSU6JRWK=
CO-314 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[wNXhKSzVyPUGxMlI5PDJizszN MY\TRW5ITVJ?
IST-MEL1 M3P4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXITWM2OD1zMT61N|I{KM7:TR?= MknpV2FPT0WU
KNS-81-FD NHXXcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPMOnpKSzVyPUGxMlU2OjdizszN NXfT[GNvW0GQR1XS
SW1463 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLkW5PFkh|ryP MVnTRW5ITVJ?
NCI-H23 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn3VphKSzVyPUGxMlY2PTJizszN MXTTRW5ITVJ?
SK-MEL-2 NEfV[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LwfWlEPTB;MUGuO|E6PyEQvF2= MXjTRW5ITVJ?
NB13 NXzjRZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnUPWJpUUN3ME2xNk4yPDl3IN88US=> M3;NdXNCVkeHUh?=
Daoy NGGwbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;vTWM2OD1zMj6yPFU3KM7:TR?= M4[5RXNCVkeHUh?=
NCI-H1623 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF{LkO4NFEh|ryP M1HWd3NCVkeHUh?=
NMC-G1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvRcHBKSzVyPUGyMlcyPyEQvF2= NFi2fFZUSU6JRWK=
DK-MG M4e0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LNZWlEPTB;MUKuPVQ5OiEQvF2= MnzpV2FPT0WU
TCCSUP NVvUbZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHvSIpsUUN3ME2xN{4yOjh2IN88US=> NHn5OWRUSU6JRWK=
SCC-15 NEfUdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULWSZltUUN3ME2xN{4zPjVzIN88US=> NE\2eINUSU6JRWK=
NOS-1 NFPWNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnhTWM2OD1zMz6yPFk{KM7:TR?= MnnUV2FPT0WU
RH-1 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT1TWM2OD1zMz6zNFM4KM7:TR?= NHflfoZUSU6JRWK=
SK-MEL-3 NUDiS4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXYTWM2OD1zMz6zO|I5KM7:TR?= NFTMXmhUSU6JRWK=
NB5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF|LkSwOlch|ryP NFToeZBUSU6JRWK=
SNU-387 M1LJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT0TWM2OD1zMz61NFczKM7:TR?= NV;SOZo5W0GQR1XS
CAL-120 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaTWM2OD1zMz62O|E5KM7:TR?= M2TvcnNCVkeHUh?=
Mo-T NXTsNWUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF|LkewO{DPxE1? MWTTRW5ITVJ?
LNCaP-Clone-FGC Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfyVZdKSzVyPUGzMlc6QTJizszN Ml\MV2FPT0WU
CAN NEPybHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjkVmdKSzVyPUG0MlAzQDhizszN MXLTRW5ITVJ?
SK-MEL-30 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDzVohVUUN3ME2xOE4xPjNizszN MkWyV2FPT0WU
COLO-678 NYfGWlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF2LkC4NlIh|ryP NIXoU2pUSU6JRWK=
SCC-9 M1K5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrtb4RKSzVyPUG0MlExOjFizszN MojBV2FPT0WU
KINGS-1 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu3Tm5KSzVyPUG0MlE1ODJizszN NVPFTo9IW0GQR1XS
SL-513 NWG0Upd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF2LkG4O{DPxE1? M2HtTHNCVkeHUh?=
HLE M33VfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDDXGhiUUN3ME2xOE4{QDV{IN88US=> NGH5RmVUSU6JRWK=
SW1573 NYXwUlJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3JWmNnUUN3ME2xOE41PDN3IN88US=> Mn7IV2FPT0WU
KYSE-140 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnEZ5p1UUN3ME2xOE43OzJ5IN88US=> NWrkbo5FW0GQR1XS
SK-PN-DW M2rFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL5WpJKSzVyPUG0MlgxODFizszN NEPGV5pUSU6JRWK=
A253 NGDaVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInG[mpKSzVyPUG1MlA3OjVizszN M1XWNHNCVkeHUh?=
CAL-12T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvUfYxKSzVyPUG1MlQ3PjJizszN M{\uRnNCVkeHUh?=
COLO-679 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHSTWM2OD1zNT63Olg{KM7:TR?= Mn;ZV2FPT0WU
UACC-257 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\hTWM2OD1zNj6xNlAyKM7:TR?= M4L5[HNCVkeHUh?=
U-87-MG M3TUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF4LkO1NlMh|ryP M1f4R3NCVkeHUh?=
HCC1806 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwfHNzUUN3ME2xOk44ODdzIN88US=> NXP4OWNmW0GQR1XS
NCI-H2170 M2TDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu1TWM2OD1zNz6yOFQ5KM7:TR?= NGHkNWRUSU6JRWK=
AGS NIHqc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF5LkO4NFgh|ryP M3;yZXNCVkeHUh?=
MEL-HO NXfhWnNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTTenNEUUN3ME2xO{44PTB|IN88US=> M2rWSXNCVkeHUh?=
SW48 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnNTWM2OD1zNz63O|E3KM7:TR?= NITofndUSU6JRWK=
HuP-T4 NI\xPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK4UYNKSzVyPUG4MlAzODZizszN MUnTRW5ITVJ?
NCI-H720 NUPPXHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\MWG5KSzVyPUG4MlE1ODJizszN NYrHc5JPW0GQR1XS
RCC10RGB NW\rfY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\afXdTUUN3ME2xPE4yPjl5IN88US=> MojxV2FPT0WU
HD-MY-Z NFHNXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4eYdzUUN3ME2xPE4zOjV2IN88US=> NXzhbYZkW0GQR1XS
A427 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF6LkWwPVQh|ryP NFLoUI9USU6JRWK=
HCC2998 M1fwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrQbZdTUUN3ME2xPE43ODVzIN88US=> NV7EZZVRW0GQR1XS
EPLC-272H NGG5TphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF7LkC0N|Qh|ryP NXe4d5lKW0GQR1XS
C32 M{HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnXSXhKSzVyPUG5MlA1PSEQvF2= NHToT4NUSU6JRWK=
UMC-11 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2PGdKSzVyPUG5MlIyOjNizszN NYL2cXFyW0GQR1XS
CaR-1 NEC5enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\sTWM2OD1zOT62PFA1KM7:TR?= MonuV2FPT0WU
KYSE-410 M4TRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF7LkmxN|kh|ryP NVX2[GROW0GQR1XS
HuCCT1 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofOTWM2OD1{MD62Nlk1KM7:TR?= MoPDV2FPT0WU
LB996-RCC NV\MOolpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHVTWM2OD1{MD63NVY5KM7:TR?= M2HKNXNCVkeHUh?=
KYSE-70 NHLqfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJyLkiwOVkh|ryP M{DubXNCVkeHUh?=
CAL-72 NVn5[mxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPwTWM2OD1{MD65NVUh|ryP NFvrTpFUSU6JRWK=
Capan-2 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3wOm1KSzVyPUKxMlA1OTNizszN NV\adpU6W0GQR1XS
PANC-08-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvkTWM2OD1{MT6yOVE2KM7:TR?= NWHkWGM4W0GQR1XS
SBC-1 M1nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHiTWM2OD1{MT6zNFgyKM7:TR?= NV;iUFhKW0GQR1XS
MFM-223 M2niNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TBSWlEPTB;MkGuN|M1OiEQvF2= NFr1N5VUSU6JRWK=
BB49-HNC NXH1dolTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqS|l2UUN3ME2yNU42PzF4IN88US=> NVfOc4NRW0GQR1XS
SH-4 NYLmO45OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ezbWlEPTB;MkGuOlYyQCEQvF2= NX3UOXpZW0GQR1XS
HuO9 NV64PWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJzLkm4NlUh|ryP NWHYTZpCW0GQR1XS
AM-38 NFLvZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDtTWM2OD1{Mj6wOFg2KM7:TR?= MlLFV2FPT0WU
A431 M3\6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXydIxKSzVyPUKzMlIyOTlizszN NH;D[|dUSU6JRWK=
YAPC NGfv[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ|LkK2OVEh|ryP MoT2V2FPT0WU
LU-139 M4P6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ|LkS4NFkh|ryP MXvTRW5ITVJ?
HEC-1 M1LKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ|LkS5N|ch|ryP MWfTRW5ITVJ?
SCC-25 M3nIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLOTWM2OD1{ND6zNFA3KM7:TR?= M{\GUnNCVkeHUh?=
HT-29 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3VmlEPTB;MkSuN|gzOyEQvF2= MXPTRW5ITVJ?
PC-14 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJTWM2OD1{ND62OVcyKM7:TR?= M2LiUnNCVkeHUh?=
Calu-6 M4DNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTmTWM2OD1{NT61NFcyKM7:TR?= NEfZeZFUSU6JRWK=
SJRH30 NXO3dXlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHScJhRUUN3ME2yOU43PDl4IN88US=> NGrIdmtUSU6JRWK=
ChaGo-K-1 M4DqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:5UWNIUUN3ME2yOk4yPjJ7IN88US=> NVXDWHdCW0GQR1XS
IA-LM NH73TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2ZpdKSzVyPUK2MlM3PDVizszN NUDO[3BNW0GQR1XS
GP5d Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTrSoJzUUN3ME2yOk41PDlzIN88US=> NFj5U4JUSU6JRWK=
NCI-H2291 M3W5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm5OZBKSzVyPUK2MlY2PDFizszN NEP3SodUSU6JRWK=
BALL-1 NVnlO21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr4T4RoUUN3ME2yOk46Ozl5IN88US=> NXvUbZpxW0GQR1XS
HCC1954 NUPxfHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7WcIJnUUN3ME2yOk46QDB6IN88US=> MljNV2FPT0WU
NCI-H2452 NHTRVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\IU3RWUUN3ME2yO{41OTZ|IN88US=> Mom0V2FPT0WU
LU-99A NImw[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ5LkW1PFIh|ryP MVzTRW5ITVJ?
NTERA-S-cl-D1 NUnGTYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDzR4RGUUN3ME2yO{44Ojl7IN88US=> M3L1VnNCVkeHUh?=
PANC-10-05 M2PEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHLdJYzUUN3ME2yO{44Pzd3IN88US=> Mmn4V2FPT0WU
NCI-H2405 NVv5T4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrVTWM2OD1{Nz65N|g4KM7:TR?= NVrTTldiW0GQR1XS
MDA-MB-415 NXLXW3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXuPJVKSzVyPUK4MlQyOzdizszN M2DWN3NCVkeHUh?=
NCI-H2342 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe2PWRzUUN3ME2yPE42OjhzIN88US=> MWrTRW5ITVJ?
TGBC24TKB MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu0TWM2OD1{OD63NVE4KM7:TR?= M{nnOHNCVkeHUh?=
LU-134-A MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrSTWM2OD1{OD65NlYyKM7:TR?= MlXSV2FPT0WU
SCC-4 NF;HVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTNzLkC0PVQh|ryP MljsV2FPT0WU
Saos-2 NF31bFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\KTWM2OD1|MT65N|A3KM7:TR?= NX:0WI1qW0GQR1XS
RERF-LC-MS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPlS25KSzVyPUOyMlgzOzFizszN MnjVV2FPT0WU
M14 NVvFT|F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1U2lEPTB;M{KuPVc3PCEQvF2= Mn3HV2FPT0WU
HPAF-II NUDFTlV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rxbmlEPTB;M{OuOVAyOSEQvF2= M3zMVHNCVkeHUh?=
NCI-H1755 M1rocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi4TYJKSzVyPUO0MlM{ODVizszN M{PzdXNCVkeHUh?=
D-392MG NGTJU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTN3Lki2O|Qh|ryP M1;xTnNCVkeHUh?=
A704 NIXtZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN4LkC0Nlch|ryP M3r1VnNCVkeHUh?=
CP50-MEL-B NUTic2hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHFTWM2OD1|Nj6xPVEyKM7:TR?= MkO3V2FPT0WU
EW-18 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:4S4FKSzVyPUO2MlQ2OiEQvF2= NFvXU5FUSU6JRWK=
WM-115 NXO0UnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr4cmJKSzVyPUO2MlgxQTlizszN NESy[XdUSU6JRWK=
LU-65 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LpPWlEPTB;M{euNVQyPyEQvF2= Mkn2V2FPT0WU
NCI-H1563 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXlbmNKSzVyPUO3MlI1QDRizszN NFzGTYxUSU6JRWK=
DBTRG-05MG MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ThU2lEPTB;M{iuNFY6OSEQvF2= MXnTRW5ITVJ?
NCI-H630 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK3TWM2OD1|OD60O|E1KM7:TR?= M3TLZnNCVkeHUh?=
NCI-H1155 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rDRWlEPTB;M{muNlQzKM7:TR?= NGDsTWlUSU6JRWK=
OVACR-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXiSWQ2UUN3ME2zPU46OTl3IN88US=> NYK4RplEW0GQR1XS
OAW-42 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LEe2lEPTB;NECuOFI2QCEQvF2= MWHTRW5ITVJ?
JVM-2 NXfMdFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRzLkK0NVUh|ryP MmHjV2FPT0WU
C3A NHXNfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fUO2lEPTB;NEGuN|Q1PyEQvF2= MWTTRW5ITVJ?
HT55 NU\ve5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xy[WlEPTB;NEKuNlg1OSEQvF2= M4[zXHNCVkeHUh?=
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXITWM2OD12Mj6yPVc1KM7:TR?= MXfTRW5ITVJ?
MEG-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHJVHFRUUN3ME20Nk41PjF4IN88US=> M1HuOnNCVkeHUh?=
NCI-H82 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRfGlEPTB;NEOuPVg6OiEQvF2= NEe1[pNUSU6JRWK=
JEG-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yTGlEPTB;NESuPVQ4KM7:TR?= NUCyOmVXW0GQR1XS
BPH-1 NF;qRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vX[2lEPTB;NE[uN|k6QCEQvF2= Ml;TV2FPT0WU
MPP-89 M1zvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR5LkK4PVgh|ryP M4rx[XNCVkeHUh?=
ALL-PO MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR5LkSxPFgh|ryP MoDzV2FPT0WU
HT MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme1TWM2OD12Nz60PVIh|ryP NEfrW5RUSU6JRWK=
NCI-H2347 NHe3OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR6LkC3NVUh|ryP M1jw[nNCVkeHUh?=
A2780 NES1R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR7LkSyNlgh|ryP NVvyZ|Y1W0GQR1XS
KARPAS-299 NG\Cd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7PbGxGUUN3ME20PU42OTF7IN88US=> NVLGdIdJW0GQR1XS
NCI-H1651 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG4U25TUUN3ME20PU45QDJzIN88US=> MV\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; 

PubMed: 30300583     


Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells.

pRb(S807, 811) / CDK4 / CDK6 / PARP; 

PubMed: 28453226     


Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. 

LC3-I / LC3-II; 

PubMed: 28453226     


Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. 

pAMPKα(T172) / pULK1(S317); 

PubMed: 28453226     


Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. 

SMAD2 (pS255); 

PubMed: 30343527     


T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.

30300583 28453226 30343527
Growth inhibition assay
Cell viability; 

PubMed: 29670090     


Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.

29670090
Immunofluorescence
SAHF/ATRX; 

PubMed: 26988987     


DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. 

LC3B; 

PubMed: 28453226     


LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).

26988987 28453226
ELISA
PGE2; 

PubMed: 26540629     


The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.

26540629
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products3

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID